# BEFORE THE GOVERNANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

**REGULAR MEETING** 

LOCATION: VIA ZOOM

DATE: DECEMBER 4, 2025

9 A.M.

REPORTER: BETH C. DRAIN, CA CSR

CSR. NO. 7152

FILE NO.: 2025-24

	DETTI di Biumit, di Contito i / 101	
1		
2	INDEX	
3		
4	ITEM DESCRIPTION	PAGE NO.
5	OPEN SESSION	
6	1. CALL TO ORDER	3
7	2. ROLL CALL	3
8 9	3. CONSIDERATION OF AMENDMENTS TO THE CIRM EMPLOYEE CONFLICT OF INTEREST POLICY	4
10	4. PUBLIC COMMENT	NONE
11	5. ADJOURNMENT	12
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
	2	
	<u>-</u>	

	DETTI G. DIMIN, GA GSK NO. 7 132
1	DECEMBER 4, 2025; 9 A.M.
2	
3	CHAIRWOMAN GASSON: OKAY. LET'S CALL THIS
4	MEETING OF THE GOVERNANCE SUBCOMMITTEE TO ORDER.
5	AND, CLAUDETTE, WOULD YOU CALL THE ROLL PLEASE.
6	MS. MANDAC: KIM BARRETT. GEORGE
7	BLUMENTHAL.
8	DR. BLUMENTHAL: HERE.
9	MS. MANDAC: MARIA BONNEVILLE.
10	VICE CHAIR BONNEVILLE: PRESENT.
11	MS. MANDAC: ANNE-MARIE DULIEGE.
12	DR. DULIEGE: PRESENT.
13	MS. MANDAC: ELENA FLOWERS.
14	DR. FLOWERS: PRESENT.
15	MS. MANDAC: JUDY GASSON.
16	CHAIRWOMAN GASSON: HERE.
17	MS. MANDAC: VITO IMBASCIANI.
18	CHAIRMAN IMBASCIANI: PRESENT.
19	MS. MANDAC: PAT LEVITT.
20	DR. LEVITT: PRESENT.
21	MS. MANDAC: LINDA MALKAS.
22	DR. MALKAS: HERE.
23	MS. MANDAC: ADRIANA PADILLA.
24	DR. PADILLA: HERE.
25	MS. MANDAC: JOYCE SACKEY.
	3

1	DR. SACKEY: PRESENT.
2	MS. MANDAC: OKAY. THANK YOU SO MUCH.
3	BACK TO YOU, JUDY. WE HAVE QUORUM.
4	CHAIRWOMAN GASSON: THANK YOU VERY MUCH,
5	CLAUDETTE.
6	SO WE'RE GOING TO BE TALKING ABOUT
7	MODIFICATIONS TO THE CONFLICT OF INTEREST GUIDANCE
8	FOR THE EMPLOYEES OF CIRM. AND SO I'LL TURN IT OVER
9	TO RAFAEL. THANK YOU, RAFAEL.
10	MR. AGUIRRE-SACASA: THANK YOU, JUDY. AND
11	GOOD MORNING, EVERYBODY. THANK YOU FOR BEING HERE.
12	LET ME SHARE MY SCREEN HERE. I WAS ABLE TO DO IT
13	EARLIER, SO HOPEFULLY THOSE TECHNICAL SKILLS STILL
14	WORK. EVERYONE SEE THAT?
15	CHAIRWOMAN GASSON: YES.
16	MR. AGUIRRE-SACASA: OKAY. THANK YOU.
17	ALL RIGHT.
18	AS JUDY SAID, I'LL BE WALKING YOU THROUGH
19	SOME PROPOSED AMENDMENTS TO THE EMPLOYEE CONFLICT OF
20	INTEREST POLICY. I'M GOING TO START WITH SOME
21	BACKGROUND. THE POLICY WAS FIRST ADOPTED IN 2005
22	AND IS DESIGNED TO ENSURE IMPARTIALITY,
23	TRANSPARENCY, AND PUBLIC TRUST BY PREVENTING CIRM
24	EMPLOYEES FROM PARTICIPATING IN MATTERS WHERE
25	PERSONAL, PROFESSIONAL, AND FINANCIAL INTEREST COULD

1	INFLUENCE OR APPEAR TO INFLUENCE THEIR OFFICIAL
2	DUTIES.
3	THE JUNE AMENDMENTS STRENGTHENED THESE
4	SAFEGUARDS BY CLARIFYING DEFINITIONS, EXPANDING
5	PARTICIPATING RESTRICTIONS, AND FORMALIZING THE
6	DISCLOSURE AND RESOLUTION PROCESS. SO PLEASE STOP
7	ME AT ANY POINT IF YOU HAVE ANY QUESTIONS.
8	THESE SLIDES THIS IS PRETTY
9	STRAIGHTFORWARD STUFF, BUT I'LL GET INTO IT FIRST.
10	THE FIRST THING WE DID IS, AS YOU SAW IN THE MEMO
11	AND THE REDLINES, IS THAT WE ALIGNED THE DEFINITION
12	OF AN IMMEDIATE FAMILY MEMBER WITH THE POLITICAL
13	REFORM ACT, THE PRA, ENSURING CONSISTENCY WITH STATE
14	LAW. THEN WE EXPANDED THE CIRCUMSTANCES UNDER WHICH
15	AN EMPLOYEE MUST REFRAIN FROM PARTICIPATING IN THE
16	REVIEW OF AN APPLICATION OR A CONTRACT.
17	SPECIFICALLY, WE CLARIFIED THE DEFINITIONS
18	OF IMMEDIATE FAMILY MEMBER TO ALIGN WITH THE PRA.
19	THAT WAY OUR EMPLOYEES WILL NOT REVIEW ANY
20	APPLICATIONS WHERE THEY HAVE AN IMMEDIATE FAMILY
21	MEMBER WHO HAS AN INTEREST.
22	IN ADDITION, WE EXPANDED THE RESTRICTIONS
23	TIED TO EMPLOYEE/FAMILY EMPLOYMENT AT APPLICATION
24	INSTITUTIONS AS I JUST MENTIONED. WE CLARIFIED THE
25	TERM "FINANCIAL BENEFIT" TO, AGAIN, ALIGN WITH THE

1	PRA, WHICH INCLUDES BOTH DIRECT AND INDIRECT
2	MONETARY GAIN.
3	WE CLARIFIED THAT A CIRM EMPLOYEE MAY NOT
4	PARTICIPATE IN THE REVIEW OF AN APPLICATION FROM A
5	PRINCIPAL INVESTIGATOR WHO IS OR HAS BEEN A RESEARCH
6	COLLABORATOR, A FORMER TRAINEE, OR A MENTOR OF THE
7	EMPLOYEE WITHIN THE LAST THREE YEARS. WE ALSO
8	REAFFIRMED THAT AN EMPLOYEE CANNOT ASSIST IN THE
9	PREPARATION OF AN APPLICATION WHERE THEY HAVE A
10	CONFLICT OR A PERCEIVED CONFLICT BEYOND PROVIDING
11	INFORMATION THAT IS ALREADY PUBLIC INFORMATION,
12	ANSWERING QUESTIONS BASED ON OUR PUBLIC
13	DOCUMENTATION OR PUBLICLY AVAILABLE INFORMATION, ET
14	CETERA.
15	FINALLY, IT INCLUDES NEW INVESTMENT
16	RESTRICTIONS. NOW EMPLOYEES CANNOT INVEST OR TRADE
17	IN A COMPANY THAT HAS RECEIVED OR APPLIED FOR
18	FUNDING FROM CIRM OR TO A COMPANY THAT A REASONABLE
19	PERSON, BASED ON PUBLICLY AVAILABLE INFORMATION,
20	WOULD NOTE DEVOTES 20 PERCENT OR MORE OF ITS
21	RESEARCH BUDGET TO CELL AND GENE THERAPY RESEARCH.
22	IF SUCH A CONFLICT ARISES, THE EMPLOYEE MUST
23	INITIATE DIVESTITURE WITHIN 90 DAYS OF OBTAINING
24	SUCH INFORMATION OF THE CONFLICT AND MAY NOT
25	PARTICIPATE OBVIOUSLY IN ANY REVIEW OF THE

1	APPLICATION OR THE CONTRACT. DIVERSIFIED MUTUAL
2	FUNDS REMAIN EXEMPT, AND INVESTMENTS UNDER \$10,000
3	CONTINUE TO BE GOVERNED BY THE PRA.
4	ANY QUESTIONS ON THIS? OKAY. CLAUDETTE,
5	LET ME KNOW IF YOU SEE ANY. THANK YOU.
6	MOVING ON TO THE NEXT SLIDE, FIRST, WE
7	CLARIFIED PROFESSIONAL ACTIVITIES TO ALLOW
8	UNCOMPENSATED, VOLUNTARY CLINICAL FACULTY ROLES FOR
9	EMPLOYEES IF THEY HAVE NO FINANCIAL BENEFIT AND NO
10	LINK TO CIRM-FUNDED PROJECTS.
11	AND THEN THE REALLY BIG CHANGE HERE IS
12	THAT WE STRENGTHENED AND FORMALIZED OUR DISCLOSURE
13	AND COMPLIANCE FRAMEWORK. EMPLOYEES ARE NOW
14	REQUIRED TO SUBMIT BOTH AN INITIAL AND ANNUAL
15	DISCLOSURE OF ANY POTENTIAL OR KNOWN CONFLICTS.
16	THEY MUST REPORT NEW AND CHANGED CONFLICTS WITHIN
17	FIVE BUSINESS DAYS TO THE LEGAL DEPARTMENT. ANY
18	EMPLOYEE WHO IDENTIFIES A CONFLICT OR A POTENTIAL
19	CONFLICT MUST IMMEDIATELY RECUSE THEMSELF FROM ALL
20	APPLICANT-RELATED ACTIVITIES UNTIL RESOLUTION. THE
21	LEGAL DEPARTMENT WOULD THEN CONDUCT A FORMAL REVIEW,
22	ISSUE A WRITTEN DETERMINATION OF THE FINDINGS, AND
23	DOCUMENT THE OUTCOMES. AND THEN, FINALLY, WE
24	INCORPORATED DISCIPLINARY CONSEQUENCES FOR FAILURE
25	TO DISCLOSE OR COMPLY WITH THESE REQUIREMENTS.

1	WE FEEL THAT THESE ENHANCEMENTS CREATE A
2	MORE CONSISTENT PROCESS FOR IDENTIFYING AND
3	RESOLVING EMPLOYEE CONFLICTS. AND WITH THESE
4	AMENDMENTS FULLY IMPLEMENTED AND REVIEWED BY STAFF
5	EMPLOYEES, WE REQUEST THAT THE GOVERNANCE
6	SUBCOMMITTEE RECOMMEND ICOC APPROVAL OF THE AMENDED
7	EMPLOYEE CONFLICT OF INTEREST POLICY. THANK YOU.
8	CHAIRWOMAN GASSON: ANY QUESTIONS FOR
9	RAFAEL AT THIS POINT? I DON'T SEE ANY HANDS RAISED.
10	DO YOU, CLAUDETTE?
11	MS. MANDAC: NO. WE DON'T SEE ANY HANDS
12	ON OUR SIDE EITHER.
13	CHAIRWOMAN GASSON: OKAY. SO, RAFAEL,
14	WOULD YOU LIKE US TO PASS A MOTION TO APPROVE TO
15	RECOMMEND TO THE FULL BOARD THAT THEY APPROVE?
16	MR. AGUIRRE-SACASA: I WOULD, JUDY.
17	CHAIRWOMAN GASSON: OKAY. I'LL ENTERTAIN
18	A MOTION TO RECOMMEND TO THE FULL BOARD THESE
19	VITO, ARE YOU
20	CHAIRMAN IMBASCIANI: I'M GOING TO MAKE A
21	MOVEMENT THAT WE ACCEPT THE RECOMMENDATION. THANK
22	YOU.
23	CHAIRWOMAN GASSON: THANK YOU, VITO. DO
24	WE HAVE A SECOND PLEASE?
25	DR. BLUMENTHAL: SECOND.
	8
	· · · · · · · · · · · · · · · · · · ·

1	CHAIRWOMAN GASSON: THANK YOU VERY MUCH,
2	GEORGE.
3	DO YOU NEED TO CALL THE ROLL FOR THIS
4	BECAUSE I THINK SOME PEOPLE ARE NOT ON CAMERA?
5	MR. TOCHER: WE DO NEED TO CALL THE ROLL,
6	JUDY, AFTER COMMENT.
7	CHAIRWOMAN GASSON: THANK YOU. ANY
8	COMMENTS FROM MEMBERS OF THE COMMITTEE AT THIS POINT
9	IN TIME?
10	CHAIRMAN IMBASCIANI: RAFAEL, I HAD A
11	QUESTION. WHO DETERMINES THE 20-PERCENT FIGURE?
12	DOES THAT ASSUME THAT CIRM HAS ACCESS TO THESE
13	COMPANY'S BUSINESS REPORTS?
14	MR. AGUIRRE-SACASA: WELL, AGAIN, IT'S
15	PUBLIC IT'S BASED ON PUBLICLY AVAILABLE
16	INFORMATION. THE INITIAL THRESHOLD REVIEW WOULD BE
17	DONE BY THE EMPLOYEE. OBVIOUSLY THEY CAN CONSULT
18	WITH THE LEGAL DEPARTMENT AT ANY TIME, BUT WE WOULD
19	MAKE THE FINAL DETERMINATION IF THEY DISCLOSE IT,
20	VITO.
21	CHAIRMAN IMBASCIANI: THANK YOU.
22	MR. AGUIRRE-SACASA: AND WE'RE TRACKING
23	ALL THE DISCLOSURES IN A DATABASE. SORRY. I SHOULD
24	HAVE SAID THAT. SO WE'LL KEEP MONITORING THIS ON A
25	REGULAR BASIS OBVIOUSLY.

1	CHAIRWOMAN GASSON: OKAY. THANK YOU VERY
2	MUCH. ANY OTHER QUESTIONS OR COMMENTS? YES,
3	PLEASE, GO AHEAD, JOYCE.
4	DR. SACKEY: THANK YOU, JUDY. RAFAEL, YOU
5	ALLUDED TO DISCIPLINARY ACTIONS IN CASE OF FAILURE
6	TO DISCLOSE OR COMPLY. CAN YOU SPEAK A LITTLE BIT
7	MORE TO THE NATURE OF THIS DISCIPLINARY ACTION?
8	MR. AGUIRRE-SACASA: SURE. I MEAN
9	HONESTLY, JOYCE, IT WOULD DEPEND ON THE FACTS AND
10	CIRCUMSTANCES OF EACH CASE. BUT IT WOULD LET'S
11	BE CLEAR. IT WOULD INCLUDE UP TO INCLUDING
12	TERMINATION. SO IF THE VIOLATION IS PERCEIVED AS
13	WILLFUL OR THERE'S MISREPRESENTATION, THERE WOULD BE
14	RECOMMENDATIONS FOR TERMINATION OF THE EMPLOYEE.
15	DR. SACKEY: THANK YOU, RAFAEL.
16	CHAIRWOMAN GASSON: CLAUDETTE, DO YOU SEE
17	ANY HANDS RAISED FROM EITHER THIS COMMITTEE OR FROM
18	THE PUBLIC AT THIS POINT IN TIME?
19	MS. MANDAC: THERE ARE NO OTHER HANDS
20	RAISED, JUDY.
21	CHAIRWOMAN GASSON: OKAY. THEN I THINK WE
22	CAN CALL THE ROLL. SCOTT, WOULD YOU LIKE TO CALL
23	THE ROLL.
24	MR. TOCHER: SURE. GEORGE BLUMENTHAL.
25	DR. BLUMENTHAL: YES.

	DETH G. DRAIN, GA GSR NO. 7 132
1	MR. TOCHER: MARIA BONNEVILLE.
2	VICE CHAIR BONNEVILLE: YES.
3	MR. TOCHER: ANNE-MARIE DULIEGE.
4	ANNE-MARIE, I THINK YOU'RE MUTED. I'LL COME BACK.
5	ELENA FLOWERS.
6	DR. FLOWERS: YES.
7	DR. DULIEGE: THIS IS ANNE-MARIE. I
8	APPROVE. SORRY ABOUT THAT.
9	MR. TOCHER: THANK YOU VERY MUCH. AND I
10	HEARD AYE FROM ELENA. AND JUDY GASSON.
11	CHAIRWOMAN GASSON: YES.
12	MR. TOCHER: VITO IMBASCIANI.
13	CHAIRMAN IMBASCIANI: YES.
14	MR. TOCHER: PAT LEVITT.
15	DR. LEVITT: YES.
16	MR. TOCHER: LINDA MALKAS.
17	DR. MALKAS: YES.
18	MR. TOCHER: ADRIANA PADILLA.
19	DR. PADILLA: YES.
20	MR. TOCHER: AND JOYCE SACKEY.
21	DR. SACKEY: YES.
22	MR. TOCHER: THANK YOU VERY MUCH. THE
23	MOTION CARRIES, JUDY.
24	CHAIRWOMAN GASSON: THANK YOU VERY MUCH,
25	SCOTT. I DON'T THINK WE HAVE ANY OTHER FORMAL
	11

11

1	MATTERS ON THE AGENDA AT THIS POINT IN TIME. ARE
2	THERE ANY OTHER MATTERS THAT MEMBERS OF THE
3	COMMITTEE WOULD LIKE TO BRING UP AT THIS TIME?
4	SEEING NO HANDS, ARE THERE ANY HANDS RAISED FROM THE
5	PUBLIC ABOUT ANY OTHER MATTERS?
6	MS. MANDAC: THERE ARE NO HANDS RAISED,
7	JUDY.
8	CHAIRWOMAN GASSON: OKAY. WELL, I THINK
9	THIS MIGHT BE A RECORD IN TERMS OF OUR
10	MR. AGUIRRE-SACASA: I'M SHOCKED WE DID
11	NOT HAVE MORE PUBLIC INTEREST IN THIS MEETING.
12	CHAIRWOMAN GASSON: EXACTLY. I'M SHOCKED.
13	I THINK THIS MIGHT HOLD THE RECORD OF OUR SHORTEST
14	MEETING. SO THANK YOU ALL SO MUCH FOR BEING HERE
15	TODAY. I APPRECIATE IT. AND WE'LL SEE YOU AT THE
16	BOARD MEETING NEXT WEEK.
17	(THE MEETING WAS THEN CONCLUDED AT 9 A.M.)
18	
19	
20	
21	
22	
23	
24	
25	

1	
2	
3	
4	REPORTER'S CERTIFICATE
5	
6	
7	I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN
8	AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE VIRTUAL PROCEEDINGS
9	BEFORE THE GOVERNANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE
10	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON DECEMBER
11	4, 2025, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE
12	STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY
13	ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.
14	
15	
16	BETH C. DRAIN, CA CSR 7152 133 HENNA COURT
17	SANDPOINT, IDAHO (208) 920-3543
18	
19	
20	
21	
22	
23	
24	
25	
	13